ENTA — ENANTA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1177648 ·
Last close
$13.70
Market Cap
$398.37M
52W High
$15.93
52W Low
$10.86
ADV30
241,481
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 17,159,000 | — | -11,852,000 | -13,091,000 | 314,704,000 | 34,928,000 | 198,117,000 |
| Dec 2025 | 18,615,000 | — | -11,253,000 | -11,938,000 | 329,503,000 | 37,437,000 | 202,912,000 |
| Sep 2025 | 15,125,000 | — | -18,386,000 | -18,700,000 | 280,732,000 | 32,298,000 | 216,015,000 |
| Jun 2025 | 18,314,000 | — | -18,893,000 | -18,255,000 | 301,029,000 | 44,812,000 | 221,750,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,838,000
Investing CF
$-59,543,000
Financing CF
$42,096,000
CapEx
$-1,771,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.59
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-429,958,000
Inventory
—
Receivables
$7,828,000
ST Investments
$128,846,000
EBIT TTM
$-51,488,000
Pretax Income TTM
$-61,892,000
Interest Exp TTM
$10,404,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$69,213,000
EBITDA
$-55,451,000
Free Cash Flow
$7,687,500
Enterprise Value
$437,209,920
Total Cash
$163,774,000
Total Debt
$186,616,992
Shares Out
29,078,380
Trailing EPS
$-2.60
Book Value
$4.01
ROE
-59.0%
ROA
-11.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 65,324,000 | -85,349,000 | -81,889,000 | 280,732,000 | 216,015,000 | — | -19,272,000 |
| Sep 2024 | 67,635,000 | -121,691,000 | -116,045,000 | 376,652,000 | 247,838,000 | — | -78,764,000 |
| Sep 2023 | 79,204,000 | -137,207,000 | -133,816,000 | 462,275,000 | 245,540,000 | — | -103,154,000 |
| Sep 2022 | 86,160,000 | -123,844,000 | -121,755,000 | 375,410,000 | 54,076,000 | — | -84,782,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABEO | ABEONA THERAPEUTICS INC. | $397.83M | $6.98 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $399.34M | $4.99 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $393.14M | $0.37 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $407.20M | $8.00 | — |
| PTCHF | PureTech Health plc | $388.74M | $1.60 | — |
News headlines (Yahoo Finance, 1h cache)
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
2026-06-24 13:13 · Yahoo
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
2026-06-23 09:10 · Yahoo
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
2026-06-18 11:00 · Yahoo
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
2026-05-11 21:10 · Yahoo
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 21:55 · Yahoo
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
2026-05-07 13:02 · Yahoo
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
2026-03-15 22:41 · Yahoo
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
2026-02-12 17:00 · Yahoo
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
2026-02-09 22:05 · Yahoo
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
2026-02-09 21:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.